ETF Holdings Breakdown of RYTM

RYTM institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	11,728	USD 1,293,364
2025-10-17	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	71,771	USD 7,914,906
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	41,964	USD 4,627,790
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	41,964	USD 4,627,790
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	37,039	USD 4,084,661
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	212	USD 23,379
Total =		204,678	USD 22,571,890

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with RYTM

FDA Accepts Rhythm Pharma' SNDA For Setmelanotide To Treat Acquired Hypothalamic Obesity

(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypotha - 2025-08-20 22:52:50

Chicago Partners Investment Group LLC Sells 186 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Chicago Partners Investment Group LLC reduced its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 5.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,510 shares of the company’s stock after selling 186 shares during the period. Chicago Partners Investment Group LLC’s holdings […] - 2025-08-13 05:18:50

Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $91.93

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned an average rating of “Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts […] - 2025-08-04 02:26:49

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Holdings Lifted by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,326 shares of the company’s stock after acquiring an additional 174 shares during the […] - 2025-08-01 05:01:17

Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to “Hold”

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. RYTM has been the subject of several other reports. Oppenheimer boosted their target price on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the company an […] - 2025-07-28 04:00:47

Bank of New York Mellon Corp Sells 1,661 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Bank of New York Mellon Corp reduced its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.1% in the first quarter, HoldingsChannel reports. The firm owned 146,585 shares of the company’s stock after selling 1,661 shares during the period. Bank of New York Mellon Corp’s holdings in Rhythm Pharmaceuticals were worth $7,765,000 at […] - 2025-07-23 04:34:46

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective lifted by Canaccord Genuity Group from $92.00 to $105.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 17.71% from the stock’s current price. Several […] - 2025-07-20 05:22:52

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells $308,222.75 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CAO Christopher Paul German sold 3,817 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total transaction of $308,222.75. Following the transaction, the chief accounting officer directly owned 922 shares of the […] - 2025-07-14 06:10:46

Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High Following Analyst Upgrade

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $76.00 to $110.00. Oppenheimer currently has an outperform rating on the stock. Rhythm Pharmaceuticals traded as high as $89.05 and last traded at $89.00, with […] - 2025-07-11 02:50:53

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst Upgrade

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price gapped up prior to trading on Wednesday after Needham & Company LLC raised their price target on the stock from $72.00 to $95.00. The stock had previously closed at $65.14, but opened at $76.75. Needham & Company LLC currently has a buy rating on the […] - 2025-07-10 02:19:11

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of “Buy” by Brokerages

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock […] - 2025-07-07 03:16:56

Avior Wealth Management LLC Acquires Shares of 4,589 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Avior Wealth Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 4,589 shares of the company’s stock, valued at approximately $243,000. Several other institutional investors and hedge funds have also bought and sold shares of the business. Assenagon Asset […] - 2025-06-24 04:52:55

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of “Buy” from Analysts

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in […] - 2025-06-12 04:56:54

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 76,084 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 76,084 shares of the company’s stock, valued at approximately $4,259,000. A number of other hedge funds and other institutional investors have also added to or reduced their […] - 2025-06-02 05:36:58

Nuveen Asset Management LLC Sells 972 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Nuveen Asset Management LLC decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,903 shares of the company’s stock after selling 972 shares during […] - 2025-05-29 05:36:56

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,156 shares of the company’s stock after buying an additional 654 shares during […] - 2025-05-23 05:32:53

Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $75.38

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on […] - 2025-05-23 04:30:49

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 491.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,249 shares of the company’s stock after purchasing an additional 70,824 shares during the period. BNP […] - 2025-05-14 06:42:59

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Comerica Bank

Comerica Bank lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 17,113 shares of the company’s stock after selling 447 shares during the period. Comerica Bank’s holdings in Rhythm Pharmaceuticals were worth $958,000 as of its most recent filing with the […] - 2025-05-13 06:00:54

Stifel Financial Corp Has $1.09 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Stifel Financial Corp decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,516 shares of the company’s stock after selling 326 shares during the quarter. Stifel Financial Corp’s holdings in […] - 2025-05-09 05:27:01

First Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

First Trust Advisors LP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 118,337 shares of the company’s stock after buying an additional 47,575 shares during the period. First Trust Advisors LP owned 0.19% of […] - 2025-04-30 06:01:00

Legal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Legal & General Group Plc decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,803 shares of the company’s stock after selling 4,244 shares during the period. Legal & General […] - 2025-04-24 05:07:03

Invesco Ltd. Has $16.95 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Invesco Ltd. grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 14.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 302,846 shares of the company’s stock after purchasing an additional 38,429 shares during the period. Invesco Ltd.’s holdings in Rhythm Pharmaceuticals were worth $16,953,000 at the end of the […] - 2025-04-21 04:44:46

Trexquant Investment LP Takes $437,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Trexquant Investment LP bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 7,798 shares of the company’s stock, valued at approximately $437,000. A number of other large investors have also recently added to or reduced their stakes in RYTM. SRS Capital Advisors […] - 2025-04-13 05:31:02

Rhythm Pharmaceuticals (NASDAQ:RYTM) Raised to Buy at Bank of America

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm presently has a $63.00 price objective on the stock. Bank of America‘s price objective points to a […] - 2025-04-09 02:52:50

Norges Bank Acquires New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Norges Bank bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,649 shares of the company’s stock, valued at approximately $11,512,000. Norges Bank owned approximately 0.33% […] - 2025-04-08 04:48:51

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target upped by Wells Fargo & Company from $80.00 to $91.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other research firms have also recently issued reports on RYTM. Morgan Stanley restated […] - 2025-04-08 02:52:50

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up After Analyst Upgrade

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price gapped up before the market opened on Monday after Wells Fargo & Company raised their price target on the stock from $80.00 to $91.00. The stock had previously closed at $46.95, but opened at $48.33. Wells Fargo & Company currently has an overweight rating on […] - 2025-04-08 02:12:52

Corebridge Financial Inc. Has $1.52 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

Corebridge Financial Inc. decreased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,220 shares of the company’s stock after selling 2,054 shares during the period. […] - 2025-04-03 05:49:02

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of “Moderate Buy” from Analysts

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year price […] - 2025-04-03 04:54:49

Back to Listing

Disclaimer